Business Description
LAVA Therapeutics NV
ISIN : NL0015000AG6
Description
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.14 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.42 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.6 | |||||
| 3-Year EBITDA Growth Rate | -36.2 | |||||
| 3-Year EPS without NRI Growth Rate | -36 | |||||
| 3-Year FCF Growth Rate | -56.6 | |||||
| 3-Year Book Growth Rate | 86.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.71 | |||||
| 9-Day RSI | 46.51 | |||||
| 14-Day RSI | 49.39 | |||||
| 6-1 Month Momentum % | 106.29 | |||||
| 12-1 Month Momentum % | 55.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.62 | |||||
| Quick Ratio | 6.62 | |||||
| Cash Ratio | 6.4 | |||||
| Days Sales Outstanding | 127.3 | |||||
| Days Payable | 544.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | -2.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.56 | |||||
| Operating Margin % | -638.99 | |||||
| Net Margin % | -620.09 | |||||
| FCF Margin % | -586.53 | |||||
| ROE % | -63.41 | |||||
| ROA % | -34.18 | |||||
| ROIC % | -392.99 | |||||
| ROC (Joel Greenblatt) % | -1408.77 | |||||
| ROCE % | -40.62 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.75 | |||||
| PB Ratio | 1.45 | |||||
| Price-to-Tangible-Book | 1.45 | |||||
| EV-to-EBIT | 0.3 | |||||
| EV-to-EBITDA | 0.31 | |||||
| EV-to-Revenue | -1.85 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | 0.31 | |||||
| Price-to-Net-Current-Asset-Value | 1.54 | |||||
| Price-to-Net-Cash | 1.65 | |||||
| Earnings Yield (Greenblatt) % | 333.33 | |||||
| FCF Yield % | -53.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LAVA Therapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.769 | ||
| EPS (TTM) ($) | -1.57 | ||
| Beta | 0.63 | ||
| Volatility % | 110.47 | ||
| 14-Day RSI | 49.39 | ||
| 14-Day ATR ($) | 0.393655 | ||
| 20-Day SMA ($) | 3.22 | ||
| 12-1 Month Momentum % | 55.26 | ||
| 52-Week Range ($) | 1.131 - 6.47 | ||
| Shares Outstanding (Mil) | 26.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LAVA Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LAVA Therapeutics NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
LAVA Therapeutics NV Frequently Asked Questions
What is LAVA Therapeutics NV(LVTX)'s stock price today?
The current price of LVTX is $2.87. The 52 week high of LVTX is $6.47 and 52 week low is $1.13.
When is next earnings date of LAVA Therapeutics NV(LVTX)?
The next earnings date of LAVA Therapeutics NV(LVTX) is 2024-06-07 Est..
Does LAVA Therapeutics NV(LVTX) pay dividends? If so, how much?
LAVA Therapeutics NV(LVTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers